On May 8, 2024, ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company headquartered in Switzerland, announced the offering of 13.4 m common shares and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8.1 m common shares, raising aggregate gross proceeds of USD 105 m.

Homburger advised ADC Therapeutics SA on the Swiss law and tax aspects of this transaction. The Homburger team was led by Daniel Häusermann (Capital Markets, Corporate / M&A) and included Estelle Piccard and Bianca Nedwed (both Capital Markets, Corporate / M&A) as well as Stefan Oesterhelt and Philippe Weber (both Tax).